Halberd (Halberd) Price-to-Free-Cash-Flow : (As of Jun. 17, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Price-to-Free-Cash-Flow?

As of today (2024-06-17), Halberd's share price is $0.0087. Halberd does not have enough years/quarters to calculate the Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jul. 2023. Therefore GuruFocus does not calculate Price-to-Free-Cash-Flow Ratio at this moment.

The historical rank and industry rank for Halberd's Price-to-Free-Cash-Flow or its related term are showing as below:

HALB's Price-to-Free-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 31.665
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Halberd's Free Cash Flow per Share for the six months ended in Jul. 2023 was $0.00.

Halberd Price-to-Free-Cash-Flow Historical Data

The historical data trend for Halberd's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Price-to-Free-Cash-Flow Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Price-to-Free-Cash-Flow

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Price-to-Free-Cash-Flow	-	-	-

Competitive Comparison of Halberd's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Halberd's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Halberd's Price-to-Free-Cash-Flow falls into.

Halberd Price-to-Free-Cash-Flow Calculation

Halberd's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio	=	Share Price	/	Free Cash Flow per Share (TTM)
	=	0.0087	/
	=

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio

Market Cap

Free Cash Flow

Halberd (OTCPK:HALB) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.

Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.

Halberd Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Halberd's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Price-to-Free-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236